Download our guide to Managing GLP-1 Costs and Supporting Optimal Health Outcomes for ideas on how to start building your own strategy now
Exenatide extended-release may cause small, persistent nodules at injection sites
Plasma insulin-like growth factor 1 is associated with cognitive impairment in Parkinsons disease
FDA-approved for three indications with multiple active-comparator trials, cardiovascular outcomes data, and extensive post-marketing surveillance
It is the pharmacological equivalent of pointing a targeted spotlight at liver fat specifically and saying "burn this." For anyone concerned about metabolic health beyond simple weight management, this liver fat data may be the single most important differentiator between the two compounds
Eli Lilly said it will file for approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027, as it succeeds in two more late-stage trials